Vincent Medical Holdings Zukünftiges Wachstum
Future Kriterienprüfungen 2/6
Vincent Medical Holdings wird ein jährliches Gewinn- und Umsatzwachstum von 10.4% bzw. 16.1% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 10.5% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 11.9% betragen.
Wichtige Informationen
9.0%
Wachstumsrate der Gewinne
9.0%
EPS-Wachstumsrate
Medical Equipment Gewinnwachstum | 38.7% |
Wachstumsrate der Einnahmen | 18.0% |
Zukünftige Eigenkapitalrendite | 12.0% |
Analystenabdeckung | Low |
Zuletzt aktualisiert | 21 Mar 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Is Vincent Medical Holdings (HKG:1612) Using Too Much Debt?
Aug 23Investors Met With Slowing Returns on Capital At Vincent Medical Holdings (HKG:1612)
May 21Returns On Capital Are Showing Encouraging Signs At Vincent Medical Holdings (HKG:1612)
Dec 21Vincent Medical Holdings (HKG:1612) Is Experiencing Growth In Returns On Capital
Aug 29Is Vincent Medical Holdings (HKG:1612) Using Too Much Debt?
May 30Is Vincent Medical Holdings (HKG:1612) Using Too Much Debt?
Dec 15One Analyst Thinks Vincent Medical Holdings Limited's (HKG:1612) Revenues Are Under Threat
Aug 07Vincent Medical Holdings' (HKG:1612) Returns Have Hit A Wall
Aug 06Vincent Medical Holdings' (HKG:1612) Dividend Will Be Reduced To HK$0.025
May 25Vincent Medical Holdings' (HKG:1612) Dividend Will Be Reduced To HK$0.025
Apr 27Vincent Medical Holdings (HKG:1612) Will Pay A Smaller Dividend Than Last Year
Apr 07Under The Bonnet, Vincent Medical Holdings' (HKG:1612) Returns Look Impressive
Mar 08Downgrade: Here's How This Analyst Sees Vincent Medical Holdings Limited (HKG:1612) Performing In The Near Term
Jul 27Is Vincent Medical Holdings (HKG:1612) A Risky Investment?
Jun 06One Vincent Medical Holdings Limited (HKG:1612) Analyst Just Slashed Their Estimates By A Material 13%
Mar 28Vincent Medical Holdings Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Mar 25Vincent Medical Holdings (HKG:1612) Knows How To Allocate Capital
Mar 23Have Insiders Been Buying Vincent Medical Holdings Limited (HKG:1612) Shares This Year?
Mar 04I Ran A Stock Scan For Earnings Growth And Vincent Medical Holdings (HKG:1612) Passed With Ease
Feb 17Is There An Opportunity With Vincent Medical Holdings Limited's (HKG:1612) 42% Undervaluation?
Feb 04What You Need To Know About Vincent Medical Holdings Limited's (HKG:1612) Investor Composition
Jan 22Investors Who Bought Vincent Medical Holdings (HKG:1612) Shares A Year Ago Are Now Up 267%
Jan 08Has Vincent Medical Holdings Limited's (HKG:1612) Impressive Stock Performance Got Anything to Do With Its Fundamentals?
Dec 26What We Learned About Vincent Medical Holdings' (HKG:1612) CEO Compensation
Dec 14Did Vincent Medical Holdings Limited (HKG:1612) Insiders Buy Up More Shares?
Dec 02Can Vincent Medical Holdings (HKG:1612) Keep Up These Impressive Returns?
Nov 20Gewinn- und Umsatzwachstumsprognosen
Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
---|---|---|---|---|---|
12/31/2026 | 1,165 | 78 | 76 | 96 | 1 |
12/31/2025 | 982 | 69 | 68 | 88 | 1 |
12/31/2024 | 834 | 62 | 65 | 85 | 1 |
6/30/2024 | 737 | 64 | 74 | 123 | N/A |
3/31/2024 | 728 | 61 | 84 | 124 | N/A |
12/31/2023 | 718 | 57 | 93 | 125 | N/A |
9/30/2023 | 714 | 55 | 81 | 105 | N/A |
6/30/2023 | 710 | 54 | 68 | 84 | N/A |
3/31/2023 | 669 | 18 | 63 | 80 | N/A |
12/31/2022 | 629 | -17 | 57 | 76 | N/A |
9/30/2022 | 658 | -21 | 78 | 98 | N/A |
6/30/2022 | 688 | -26 | 100 | 120 | N/A |
3/31/2022 | 733 | 18 | 97 | 120 | N/A |
12/31/2021 | 778 | 61 | 94 | 119 | N/A |
9/30/2021 | 901 | 114 | 106 | 140 | N/A |
6/30/2021 | 1,024 | 167 | 118 | 162 | N/A |
3/31/2021 | 1,090 | 192 | 131 | 185 | N/A |
12/31/2020 | 1,155 | 217 | 144 | 208 | N/A |
9/30/2020 | 957 | 153 | 89 | 143 | N/A |
6/30/2020 | 758 | 90 | 34 | 79 | N/A |
3/31/2020 | 630 | 51 | 16 | 55 | N/A |
12/31/2019 | 502 | 12 | -3 | 31 | N/A |
9/30/2019 | 505 | 22 | 10 | 40 | N/A |
6/30/2019 | 507 | 32 | 24 | 50 | N/A |
3/31/2019 | 498 | 31 | 15 | 42 | N/A |
12/31/2018 | 488 | 31 | 6 | 35 | N/A |
9/30/2018 | 478 | 22 | -21 | 14 | N/A |
6/30/2018 | 468 | 14 | -47 | -8 | N/A |
3/31/2018 | 457 | 13 | N/A | -13 | N/A |
12/31/2017 | 446 | 13 | N/A | -18 | N/A |
9/30/2017 | 441 | 21 | N/A | 9 | N/A |
6/30/2017 | 435 | 29 | N/A | 36 | N/A |
3/31/2017 | 451 | 29 | N/A | 29 | N/A |
12/31/2016 | 467 | 29 | N/A | 22 | N/A |
9/30/2016 | 465 | 39 | N/A | 31 | N/A |
6/30/2016 | 462 | 48 | N/A | 40 | N/A |
3/31/2016 | 455 | 53 | N/A | 47 | N/A |
12/31/2015 | 448 | 58 | N/A | 55 | N/A |
12/31/2014 | 389 | 36 | N/A | 44 | N/A |
12/31/2013 | 324 | 23 | N/A | 41 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: 1612Das prognostizierte Gewinnwachstum (10.4% pro Jahr) liegt über der Sparquote (2.3%).
Ertrag vs. Markt: 1612Die Erträge des Unternehmens (10.4% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt Hong Kong (11% pro Jahr).
Hohe Wachstumserträge: 1612Die Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.
Einnahmen vs. Markt: 1612Die Einnahmen des Unternehmens (16.1% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Hong Kong (7.4% pro Jahr).
Hohe Wachstumseinnahmen: 1612Die Einnahmen des Unternehmens (16.1% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: 1612Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (11.9%).